H
HanchorBio
Developing a technology for the creation of next generation personalized biotherapeutics
About HanchorBio
HanchorBio is a pioneering biotech company focused on developing innovative biologics with novel modalities for cancer treatment. The company operates in the oncology and immuno-oncology markets, targeting both cancer patients and healthcare providers. Utilizing a unique IgG Fc Based Designer Biologics platform, HanchorBio creates biologic medicines that simultaneously target multiple pathways, enhancing treatment efficacy. The business model revolves around research and development, clinical trials, and subsequent licensing or direct commercialization of its biologic products. Revenue is generated through milestone payments, royalties, and product sales. HanchorBio's lead molecule, engineered IL-12, was licensed to Bristol-Myers Squibb for $475 million in near-term payments and substantial milestone-based royalties. The company is listed on the Hong Kong Stock Exchange with a valuation of $3 billion, reflecting its strong market position and growth potential.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2020
- Headquarters
- Taipei, Taiwan
- Listing
- IPO 2025
- Employees
- 53
- Open positions
- 1
- Dealroom signal
- 57.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Jul 2025 | $80M | — | Affinity Capital Management · Vivo Capital · Panacea Venture | ↗ |
| IPO✓Exit | Jun 2025 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin | Profit | Margin |
|---|---|---|---|---|---|---|
| 2026 | $9M | 0% | −$9.5M | -105.6% | −$8M | -88.6% |
| 2025 | $9M | — | −$9.5M | -105.6% | −$8M | -88.6% |
Growth signals
Latest recorded traffic for HanchorBio is 26K monthly website visits, up 348.3% over the last three months. HanchorBio's team grew 35.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Zero2IPO- YFYuexiu Industrial Fund
Panacea Venture- YCYuansheng Venture Capital
- CBChina Biopharmaceutical
Series B and later2 investors entered at this stage
Affinity Capital Management
Vivo Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about HanchorBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See HanchorBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.